Market News AIOpen the app

REPL stock news · Replimune Group Inc.

Stories about Replimune Group Inc. (REPL) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for REPL

Follow Replimune Group Inc. (REPL) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for REPL
Free on the App Store and Google Play, or on the web.
  1. Aug 7, 2026, 7:59 AM ET · Trial

    After facing two setbacks and a complicated journey, Replimune has successfully obtained FDA approval for its skin cancer therapy.

    Good for REPL

    Replimune's FDA approval for Tudriqev marks a pivotal moment for the company, allowing it to offer a new treatment for advanced skin cancer. This approval not only validates the efficacy of their therapy but also positions them favorably in the competitive oncology market, potentially leading to increased sales and market share.